Soleno Therapeutics Dirección

Dirección controles de criterios 1/4

El CEO de Soleno Therapeutics es Anish Bhatnagar , nombrado en Jan 2017, tiene una permanencia de 7.83 años. compensación anual total es $4.12M, compuesta por 13.5% salario y 86.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.1% de las acciones de la empresa, por valor de €2.45M. La antigüedad media del equipo directivo y de la junta directiva es de 0.8 años y 5.4 años, respectivamente.

Información clave

Anish Bhatnagar

Chief Executive Officer (CEO)

US$4.1m

Compensación total

Porcentaje del salario del CEO	13.5%
Permanencia del CEO	7.8yrs
Participación del CEO	0.1%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	5.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Anish Bhatnagar en comparación con los beneficios de Soleno Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$131m
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$52m
Dec 31 2023	US$4m	US$557k	-US$39m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$1m	US$557k	-US$24m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$23m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$4m	US$538k	-US$31m
Sep 30 2021	n/a	n/a	-US$31m
Jun 30 2021	n/a	n/a	-US$31m
Mar 31 2021	n/a	n/a	-US$28m
Dec 31 2020	US$3m	US$504k	-US$25m
Sep 30 2020	n/a	n/a	-US$36m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$30m
Dec 31 2019	US$822k	US$470k	-US$31m
Sep 30 2019	n/a	n/a	-US$16m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$952k	US$460k	-US$12m
Sep 30 2018	n/a	n/a	-US$16m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$1m	US$446k	-US$12m

Compensación vs. Mercado: La compensación total de Anish($USD4.12M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.92M).

Compensación vs. Ingresos: La compensación de Anish ha aumentado mientras la empresa no es rentable.

CEO

Anish Bhatnagar (54 yo)

7.8yrs

Permanencia

US$4,116,434

Compensación

Dr. Anish Bhatnagar, M.D. has been Chief Executive Officer and Director of Soleno Therapeutics, Inc. since 2017 and serves as its President and Chief Operating Officer. Prior to Soleno, Dr. Bhatnagar serve...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Anish Bhatnagar	President	7.8yrs	US$4.12m	0.10% € 2.5m
James MacKaness	Chief Financial Officer	5yrs	US$1.21m	0.070% € 1.7m
Patricia Hirano	Senior Vice President of Regulatory Affairs	no data	US$1.03m	0.091% € 2.2m
Jesse Schumaker	General Counsel	less than a year	sin datos	sin datos
Lauren Budesheim	Vice President of People	less than a year	sin datos	sin datos
Kristen Yen	Senior Vice President of Clinical Operations	no data	US$821.67k	0.027% € 644.9k
Neil Cowen	Senior Vice President of Drug Development	7.7yrs	sin datos	sin datos
Meredith Manning	Chief Commercial Officer	less than a year	sin datos	sin datos
Michael Huang	Senior Vice President of Clinical Development	less than a year	sin datos	sin datos
Raymond W. Urbanski	Chief Development Officer	less than a year	sin datos	sin datos
Mitchell Nagao	Senior Vice President of Medical Affairs	less than a year	sin datos	sin datos

0.8yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6XC no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Anish Bhatnagar	President	10.8yrs	US$4.12m	0.10% € 2.5m
James Arthur Geraghty	Member of Advisory Board	less than a year	sin datos	sin datos
William Harris	Independent Director	10.4yrs	US$111.87k	0.021% € 489.9k
Thomas Casale	Member of Advisory Board	no data	sin datos	sin datos
Andrew Sinclair	Independent Director	5.9yrs	US$51.87k	0.015% € 358.0k
Robert Christensen	Member of Advisory Board	no data	sin datos	sin datos
Vinod Bhutani	Member of Advisory Board	no data	sin datos	sin datos
Birgitte Volck	Independent Director	5.4yrs	US$102.87k	0.016% € 387.9k
Glenis Scadding	Member of Advisory Board	no data	sin datos	sin datos
Matthew Pauls	Lead Independent Director	1.3yrs	US$70.53k	0% € 0
Shamim Ruff	Chair of the Development Advisory Board	less than a year	sin datos	sin datos
David Stevenson	Member of Advisory Board	no data	sin datos	sin datos

5.4yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 6XC se considera experimentada (5.4 años de antigüedad promedio).

Soleno Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

President recently sold €966k worth of stock

President recently sold €4.9m worth of stock

Soleno Therapeutics, Inc. Announces Board Changes

President recently sold €5.3m worth of stock

President recently sold €746k worth of stock

Insufficient new directors

Recent updates

Soleno Therapeutics, Inc. Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Forecast to breakeven in 2026

Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

President recently sold €966k worth of stock

President recently sold €4.9m worth of stock

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

No longer forecast to breakeven

President recently sold €5.3m worth of stock

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

President recently sold €746k worth of stock

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

New minor risk - Share price stability

Insufficient new directors

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

President recently sold €731k worth of stock

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

New major risk - Shareholder dilution

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Insufficient new directors

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

New major risk - Financial position

No longer forecast to breakeven

No longer forecast to breakeven

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Forecast to breakeven in 2025

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Insufficient new directors

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Insufficient new directors

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Insufficient new directors

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

New 90-day low: €1.16

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

New 90-day high: €2.24

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: €1.74

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

New 90-day low: €1.36

Soleno Therapeutics, Inc. Announces the Body Composition Data from the Company’s Phase III trial, DESTINY PWS (C601)

Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors

Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

New 90-day low - €1.53

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad